Stay updated on Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial
Sign up to get notified when there's something new on the Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial page.

Latest updates to the Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial page
- Check6 days agoChange DetectedAdded Revision: v3.3.2 and removed Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check13 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1.SummaryDifference0.0%

- Check20 days agoChange DetectedThe funding notice at the top of the page was removed, eliminating the warning about potential delays and outdated information due to funding gaps. This change affects the user's visibility of the page's operating status disclaimer.SummaryDifference0.2%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe Study Details page for NCT02227238 shows no additions or deletions to core content; the study overview, design, outcomes, and IPD sharing information remain as presented. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check63 days agoChange Detected- Added a government funding lapse notice and current operating status guidance for NIH Clinical Center, and a version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference1%

- Check70 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.0%

Stay in the know with updates to Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dolutegravir vs Lopinavir/Ritonavir in Second-line Clinical Trial page.